Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Enzalutamide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Level | EXPERIMENTAL | Relacorilant will be given at a dose once daily. Enzalutamide will be given at a dose once daily. |
| Name | Type | Description |
|---|---|---|
| Enzalutamide | DRUG | Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study). |
| Relacorilant | DRUG | Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study. |
Inclusion Criteria: 1. Histologically or cytologically confirmed prostate cancer with documented metastatic disease 2. Evidence of castrate testosterone level \<50ng/dl (or surgical castration) 3. Evidence of disease progression: * 2 or more new lesions on bone scan or * Progressive disease ...
Top 20 of 53 competitors
Enzalutamide is an investigational small molecule being studied for the treatment of prostate cancer. It is currently in Phase 1 clinical development. A completed clinical trial evaluated Enzalutamide in combination with another drug, Relacorilant, in patients with prostate cancer.
Enzalutamide is being developed by Corcept Therapeutics Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol CORT. The company is conducting clinical research to evaluate the drug's potential in oncology, specifically for prostate cancer.
Enzalutamide is currently in Phase 1 clinical development for prostate cancer. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, involving 42 participants.
Enzalutamide has been studied in a completed Phase 1 clinical trial with the identifier NCT03674814. The trial, titled "Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer," enrolled 42 male patients aged 18 years and older in the United States.
No, Enzalutamide and Relacorilant are different drugs. They were studied together in a clinical trial for prostate cancer, where Enzalutamide was referred to as Drug 1 and Relacorilant as Drug 2. The trial was an uncontrolled, non-randomized study that has been completed.